The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure

Update Il y a 4 ans
Reference: EUCTR2005-003351-12

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -


The primary objective of this trial is to evaluate the efficacy and safety of eplerenone plus standard heart failure (HF) therapy versus placebo plus standard HF therapy on the cumulative incidence of cardiovascular (CV) mortality and HF hospitalization (a composite primary endpoint).

Inclusion criteria

  • Chronic systolic heart failure